Global Intravenous Immunoglobulin Market Size study & Forecast, by Application (Immunodeficiency Diseases) and Distribution Channel (Hospital Pharmacies) and Regional Forecasts 2025-2035

The Global Intravenous Immunoglobulin Market was valued at approximately USD 13.85 billion in 2024 and is poised to expand at a promising CAGR of 7.2% throughout 2025–2035. Intravenous Immunoglobulin (IVIG), a life-sustaining therapeutic solution derived from human plasma, has evolved into a cornerstone treatment for individuals suffering from immune dysfunctions. Used widely to restore immune balance, neutralize pathogens, and regulate inflammatory responses, IVIG continues carving out a central role in modern clinical care. The market’s upward trajectory is reinforced by the rising prevalence of immunodeficiency disorders, advancements in plasma-fractionation techniques, and accelerated healthcare spending across developed and emerging nations. Together, these forces are reshaping the landscape for brands striving to broaden their biologics portfolios in an increasingly competitive biopharmaceutical environment.

A substantial rise in newly diagnosed immunodeficiency conditions has amplified the dependence on IVIG therapies as clinicians push to curb disease progression and reduce life-threatening complications. Furthermore, the expanding use of IVIG in off-label indications—such as autoimmune neuromuscular disorders—has compelled manufacturers to scale up plasma collection and refine manufacturing efficiencies. The global need for immune-modulating therapies continues to climb as aging populations, lifestyle-related vulnerabilities, and chronic disease burdens grow heavier worldwide. However, the industry still grapples with persistent supply constraints, stringent regulatory frameworks, and the high cost of plasma procurement. As healthcare systems push toward advanced treatment modalities, emerging biologics and robust clinical innovations are expected to unlock deeper opportunities for investment and strategic expansion.

The detailed segments and sub-segments included in this report are:

By Application:
• Immunodeficiency Diseases

By Distribution Channel:
• Hospital Pharmacies

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Immunodeficiency diseases are projected to dominate the market landscape over the forecast horizon. This segment continues to anchor the global revenue pool, upheld by an alarming surge in patients diagnosed with primary and secondary immunodeficiencies. As healthcare systems ramp up screening programs and develop more robust diagnostic infrastructure, the number of patients eligible for IVIG therapy is rising steadily. Consequently, IVIG has transitioned from a specialized solution to a mainstream therapeutic agent that physicians rely upon to stabilize immune function, manage severe infections, and mitigate debilitating symptoms.

Hospital pharmacies currently command the largest share of revenue generation, acting as the predominant distribution channel for IVIG products across the world. Their dominance stems from the high dependency of IVIG administration on clinical supervision, strict dosing protocols, and infusion-related monitoring—responsibilities primarily handled within hospital settings. Additionally, the growing complexity of infusion regimens, the need for sterile environments, and the trend toward integrating biologics into hospital-based specialty care have established hospital pharmacies as pivotal pathways for IVIG access. While alternative distribution channels such as specialty clinics are gaining traction, hospital pharmacies remain the central gateway for high-volume and critical-use patient segments.

Across regional markets, North America emerged as the unequivocal leader in 2025, underpinned by its sophisticated healthcare infrastructure, strong reimbursement frameworks, and widespread adoption of immunoglobulin therapies. The U.S., in particular, maintains a dominant influence through its extensive plasma-collection ecosystem and persistent innovation across biologics research. Meanwhile, Asia Pacific is projected to record the fastest growth through 2035. Rapid urbanization, rising healthcare expenditures, expanding diagnostic awareness, and government support for biologics manufacturing collectively fuel the region’s momentum. As China and India push to modernize their healthcare systems, the demand for advanced immunotherapies such as IVIG is expected to accelerate significantly.

Major market players included in this report are:
• CSL Behring
• Grifols S.A.
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Kedrion Biopharma
• Biotest AG
• Baxter International Inc.
• Pfizer Inc.
• ADMA Biologics
• LFB Group
• Sanofi S.A.
• China Biologic Products Holdings, Inc.
• Emergent BioSolutions
• BPL (Bio Products Laboratory)
• Intas Pharmaceuticals Ltd.

Global Intravenous Immunoglobulin Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast Period – 2025-2035
• Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of this study is to define market sizes across multiple segments and countries in recent years and project their values for the coming decade. The report integrates a rich blend of qualitative insights and quantitative metrics to capture the nuances shaping the industry’s future trajectory. It further sheds light on major growth catalysts and structural challenges that determine market evolution, while outlining micro-market opportunities that investors and manufacturers may leverage. Additionally, the study provides a detailed competitive landscape analysis, highlighting product offerings, strategic moves, and innovations from leading companies. The full segmentation framework of the market is outlined above.

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional-level analysis for each market segment.
• Detailed analysis of the geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of the competitive structure of the market.
• Demand-side and supply-side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more